UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB

(Mark One)

[X]      QUARTERLY  REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES  EXCHANGE
         ACT OF 1934
                  For the quarterly period ended March 31, 2003

[ ]      TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

      For the transition period from _________________ to _________________

                        Commission file number 333-83152


                  Inyx, Inc. (formerly known as Doblique, Inc.)
        (Exact name of small business issuer as specified in its charter)

              Nevada                                       75-28700720
   (State or other jurisdiction                (IRS Employer Identification No.)
of incorporation or organization)


                  801 Brickell, 9th Floor, Miami, Florida 33131
                    (Address of principal executive offices)

                                 (305) 789-6699
                          (Issuer's telephone number)

       Doblique, Inc., 2591 Dallas Parkway, Suite 100, Frisco, Texas 75034
              (Former name, former address and former fiscal year,
                          if changed since last report)

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

Check whether the  registrant  filed all  documents  and reports  required to be
filed by Section l2, 13 or 15(d) of the Exchange Act after the  distribution  of
securities under a plan confirmed by a court. Yes [ ] No [ ]




<PAGE>

APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date: 24,950,000

Transitional Small Business Disclosure Format (Check one):  Yes [ ] No [X]

Include whether Registrant is an accelerated filer:    Yes [ ] No [X]







































                                       2
<PAGE>

                  INYX, INC. (formerly known AS DOBLIQUE, INC.)

                                      INDEX

Description                                                               Page
-----------                                                               ----

PART I:

Item 1.  - Financial Statements     :
         Balance Sheet as of March 31, 2003                                4
         Statements of Operations for the three
         months ended March 31, 2003 and 2002                              5
         Statements of Cash Flows for the three
         month ended March 31, 2003 and 2002                               6

Item 2. - Management's Discussion and
         Analysis of Financial Position and Results of Operations          8-10
Item 3. - Controls and Procedures                                          10


PART II:

Item 5. - Other Information                                                11
Item 6. - Exhibits and Reports on Form on Form 8-K                         11


Signatures                                                                 13



Certifications                                                             14-17


























                                       3
<PAGE>

PART I -- FINANCIAL INFORMATION

                          Item 1. Financial Statements

                  INYX, INC. (formerly known as DOBLIQUE, INC.)

                                  Balance Sheet
                                  -------------

                                     Assets
                                     ------


                                                                 March 31, 2003
                                                                   (Unaudited)
                                                                 ---------------
Current assets:
         Cash                                                    $          380
                                                                 --------------
                                                                 $          380
                                                                 ==============

                      Liabilities and Stockholders' Deficit
                      -------------------------------------

Current liabilities:
         Accounts payable - trade                                $        2,475
                  Total current liabilities                               2,475
                                                                  --------------
Commitments and contingencies

Stockholders' equity:
         Common stock - $0.001 par value
           25,000,000 shares authorized
           5,000,000 shares issued and
           outstanding                                                    5,000
Additional paid-in capital                                              214,006
Accumulated deficit                                                    (221,101)
                                                                 --------------
                  Total stockholders' deficit                            (2,095)
                                                                 --------------
Total liabilities and stockholders' deficit                      $          380
                                                                 ==============





















                                       4
<PAGE>

                  INYX, INC. (formerly known as DOBLIQUE, INC.)

                            Statements of Operations

                                                    Three months ended March 31
                                                            (unaudited)
                                                        2003            2002
                                                    -----------     -----------

Revenues:
         Racing purses                              $      --       $    11,426
                                                    -----------     -----------

Operating expenses:
         Livestock expenses:
                  Boarding and training                    --            13,595
                  Veterinarian fees                       1,728           3,409
                  Other                                    --              --
         Jockey fees and other track expenses              --               240
         Executive compensation contributed
           by controlling stockholder                     6,000           6,000
         General and administrative expenses              3,343           4,294
         Depreciation                                     3,250           4,306
                                                    -----------     -----------

                  Total operating expenses               14,321          33,429
                                                    -----------     -----------

Loss from operations                                    (14,321)        (22,003)
Other income (expense):
         Loss on sale of livestock                      (10,587)           --

Net loss                                            $   (24,908)    $   (22,003)
                                                    ===========     ===========
Loss per share of common stock outstanding
         - basic and fully diluted                  $    (0.005)    $    (0.004)
                                                    ===========     ===========
Weighted-average number of shares
  outstanding - basic and fully diluted               5,000,000       5,000,000
                                                    ===========     ===========

















                                       5
<PAGE>
<TABLE>
<CAPTION>

                                                          Three months ended March 31
                                                                   (unaudited)
                                                              2003            2002
                                                          -----------     -----------
<S>                                                       <C>             <C>
Cash flows from operating activities:
         Net loss                                         $   (24,908)    $   (22,003)
         Adjustments to reconcile net loss to
           net cash used in operating
           activities:
           Depreciation                                         3,250           4,306
           Loss on sale of livestock                           10,587            --
           Executive compensation contributed
            by a controlling stockholder                        6,000           6,000
           Decrease in accounts payable                        (5,080)           --
                                                          -----------     -----------

                  Net cash used in operating activities       (10,151)        (11,697)
                                                          -----------     -----------
Cash flows from investing activities:
         Proceeds from sale of livestock                       45,000            --
         Purchase of livestock                                   --           (16,000)
                                                          -----------     -----------
                  Net cash provided by (used in)
                    investing activities                       45,000         (16,000)
                                                          -----------     -----------
Cash flows from financing activities:
         Funds (paid to) advanced by stockholder              (59,420)          3,565
                                                          -----------     -----------
                  Net cash (used in) provided
                  by financing activities                     (59,420)          3,565
                                                          -----------     -----------

Decrease in cash                                              (24,571)        (24,132)

Cash at beginning of period                                    24,951          27,490
                                                          -----------     -----------

Cash at end of period                                     $       380     $     3,358
                                                          ===========     ===========

Supplemental disclosure of cash flow information:

Non cash financing activities:
Debt forgiveness by stockholder                           $   170,006     $      --
                                                          ===========     ===========
</TABLE>




                                       6
<PAGE>

                  INYX, INC. (formerly known as DOBLIQUE, INC.)

                          NOTES TO FINANCIAL STATEMENTS

The  information  contained  in this  report  is  unaudited,  but  reflects  all
adjustments  which are, in the opinion of the  management,  necessary for a fair
statement of results of the interim periods, consisting only of normal recurring
accruals. The results for such interim periods are not necessarily indicative of
results to be expected for the full year.

Note 1. Livestock and Accumulated Depreciation

         On March 6, 2003 the Company  sold all  Livestock  (3 horses) for total
consideration of $45,000.
<TABLE>
<CAPTION>

                                                        March 31, 2003    March 31, 2002
                                                        --------------    --------------
<S>                                                     <C>               <C>
Race Horses                                             $         --      $       65,000
Accumulated Depreciation                                $         --      $      (16,528)
Net Livestock                                           $       48,482
Accumulated depreciation at the beginning
         of the period                                  $       22,163    $       12,222
Accumulated depreciation relieved upon sale of horses   $      (25,413)   $         --
Accumulated depreciation at the end of the period       $         --      $       16,528
</TABLE>

Note 2.  Amounts Due to Stockholder

         The  Company's  controlling   Stockholder   periodically  advances  and
receives repayment of funds loaned to the Company to support operations,  settle
outstanding trade accounts payable and provide working capital. The advances are
payable  upon  demand  and  are  non-interest  bearing.  On  March  24,  2003 in
accordance with the Stock Exchange  Agreement (see Note 3 below) the controlling
Stockholder  provided a release and discharge of all liabilities to the Company,
this transaction was treated as a contribution of capital by the stockholder.

Note 3.  Capital Stock

         On February  19, 2003 the issued and  outstanding  shares  amounting to
1,000,000  were split at a forward ratio of 5 to 1, in the form of a dividend of
4,000,000 shares of common stock.

         In accordance to the terms of the Stock Exchange  Agreement dated March
24, 2003 the  controlling  Stockholder  sold  2,250,000  shares of common stock,
representing approximately 45% of the Company's issued and outstanding shares to
Medira Investments LLC.

 Note 4. Subsequent Events

         On April 17, 2003 the Company  entered into a Finders'  Fee  Agreements
with five companies (the "Finders") in connection with the proposed  acquisition
by the  Company  of all of the  issued  and  outstanding  shares of Inyx  Pharma
Limited ("Inyx  Pharama").  On closing of the proposed  acquisition  the Company
issued 2,450,000 restricted shares of Common Stock to the Finders for their role
in facilitating the transaction.


                                       7
<PAGE>

         On April 21, 2003 the Company entered into a two year Business Advisory
and Financial  Consulting Services Agreement ("the Agreement") with a consultant
to provide advice and council regarding the Company's  strategic  business plans
and other  consulting  needs.  As  consideration  for this Agreement the Company
issued 1,500,000 restricted shares of common stock.

         On April 28, 2003 the Company  acquired all the  outstanding  shares of
Inyx  Pharma  through  a share  exchange  transaction  whereby  the Inyx  Pharma
Stockholders were issued 16,000,000 shares of common stock and became the owners
of a majority  interest in the Company.  The  transaction was accounted for as a
reverse acquisition under purchase accounting rules.

         On May 1, 2003 the Company  adopted a Stock Option Plan which  provides
for the granting of options for the benefit of employees officers and directors.
The total  number  of  shares  that may be  issued  under  the plan  amounts  to
5,000,000.  The  exercise  price per share will be the fair market  price at the
time of grant and the maximum term is three years.

         On May 6, 2003 the Company changed its name to Inyx, Inc.

         Details of the  acquisition  and the resulting  business of the Company
are contained in a Form 8K dated May 13, 2003, as amended.

Item 2. Management's Discussion and Analysis of Financial Conditions and Results
of Operations

The financial  information set forth in the following  discussion should be read
in conjunction with, and qualified in its entirety by, the financial  statements
of the Company included elsewhere herein.

FORWARD-LOOKING STATEMENTS

         This quarterly report contains certain  forward-looking  statements and
information relating to the Company that are based on the beliefs of the Company
or management as well as assumptions made by and information currently available
to  the  Company  or  management.   When  used  in  this  document,   the  words
"anticipate,"   "believe,"   "estimate,"   "expect"  and  "intend"  and  similar
expressions,  as they relate to the Company or its  management,  are intended to
identify forward-looking statements. Such statements reflect the current view of
the  Company   regarding  future  events  and  are  subject  to  certain  risks,
uncertainties  and  assumptions,  including the risks and  uncertainties  noted.
Should  one or more of  these  risks or  uncertainties  materialize,  or  should
underlying assumptions prove incorrect,  actual results may vary materially from
those  described  herein  as  anticipated,   believed,  estimated,  expected  or
intended. In each instance,  forward-looking information should be considered in
light of the accompanying  meaningful  cautionary statements herein. The Company
will not undertake and specifically declines any obligation to update or correct
any forward looking statements to reflect events or circumstances after the date
of such statements or to reflect the occurrence of anticipated or  unanticipated
events.


                                       8
<PAGE>

OVERVIEW

         The Company,  was incorporated  under the laws of Nevada in March 2000.
In  July  2002,  it  became  a  publicly-traded  company  when  it  completed  a
registration  statement  for the sale,  by its  principal  stockholder,  of 2.45
million  shares of common  stock.  The  Company's  common stock is traded on the
Nasdaq's  Over-the-Counter  Bulletin Board  ("OTCBB").  The Company  voluntarily
files annual,  quarterly and periodic  reports with the  Securities and Exchange
Commission pursuant to Section 15(d) of the Securities Exchange Act of 1934.

         On February 19th,  2003, the Company issued a press release  announcing
that the Company's Board of Directors had approved a 5 for 1 forward stock split
of the Company's  common stock in the form of a dividend of 4.00 million  shares
of common stock.  The record date for the forward  split was March 3, 2003.  The
Company has been in the business of owning and racing  thoroughbred  race horses
at various major horse racing tracks  throughout the United  States.  The horses
previously owned by the Company were sold for cash on March 6, 2003.

         In accordance to the terms of the Stock Exchange  Agreement dated March
24, 2003, the Company's controlling Stockholder accepted an unsolicited offer to
sell a controlling  block,  2.25 million  shares of common  stock,  representing
approximately  45% of the  Company's  issued  and  outstanding  shares to Medira
Investments  LLC.  As  part  of  that  transaction,  the  Company's  controlling
Stockholder  also  provided a release and  discharge of all  liabilities  to the
Company.

         On March 26,  2003,  Doblique  issued a press  release  announcing  the
change of control  transaction  and that the  Company  would now pursue  further
strategic   investment   opportunities   in  a  number  of  sectors  within  the
pharmaceutical,    biotechnology   and   medical   devices   industries.   These
opportunities   would   include   research   and   development,   manufacturing,
distribution, and intellectual property acquisitions.

         On April 22, 2003, the Company  announced that it had agreed to acquire
all of the issued and  outstanding  securities  of Inyx  Pharma  Limited  ("Inyx
Pharma"),  a specialty  pharmaceutical  company  incorporated  under the laws of
England and Wales. Pursuant to that announcement, on April 17, 2003, the Company
entered into an Agreement  with five parties  where the Company  agreed to issue
2.45 million of shares of restricted  common stock as a fee to these parties for
their role in facilitating the transaction with Inyx Pharma.  On April 21, 2003,
the  Company  also  entered  into a two year  Business  Advisory  and  Financial
Consulting  Services  Agreement  with a consultant to provide advice and counsel
regarding the Company's  strategic  business  plans. As  consideration  for this
Consulting  Agreement,  the  Company  issued 1.5  million  shares of  restricted
securities to the Consultant.

         On April 28,  2003,  the  Company  concluded  its  acquisition  of Inyx
Pharma.  The  transaction  consisted  of an exchange of 100% of the  outstanding
common stock of Inyx Pharma, for 16 million shares of restricted common stock of
the  Company  (the  "Exchange"),  representing  approximately  64% of the shares
outstanding  after  that  exchange,  as a result of which Inyx  Pharma  became a
wholly owned  subsidiary  of the Company.  Inyx Pharma  focuses its expertise on
development-led  manufacturing  in the sterile  pharmaceutical,  finished-dosage
form,  outsourcing sector. It specializes in niche products and technologies for
the treatment of respiratory,  allergy, dermatological,  and topical conditions.
Inyx  Pharma's  client base is  comprised of  blue-chip  ethical  pharmaceutical
companies, branded generic firms and biotechnology groups.


                                       9
<PAGE>

         To reflect its new operating business,  the Company changed its name on
May 6, 2003 to Inyx, Inc.

RESULTS OF OPERATIONS

         Three Months Ended March 31, 2003  Compared to Three Months ended March
31, 2002

         For the three month periods ended March 31, 2003 and 2002,  the Company
generated  revenues  of -0- and  $11,426  respectively.  The  decrease is mainly
attributable to change of company  strategic focus and the sale of all livestock
on March 6, 2003.  The  disposition  of the horses was  consistent  with the new
strategic  direction the Company decided to pursue, as described above under the
Overview  section  and in the  subsequent  events  section  under Item 5 of this
report.

         The  Company's  expenses  during  these  corresponding  periods  relate
principally to training and  veterinarian  expenses.  Total  operating  expenses
decreased  to $14,321  for the three  month  period  ended  March 31,  2003 from
$33,429 for the comparable period in 2002.

         Total net losses for the  quarters  ended  March 31, 2003 and 2002 were
$24,908 and $22,003  respectively.  The net loss for the period  ended March 31,
2003 included a loss on sale of livestock of $10,587.

         Net loss per share was $0.005 and $0.004 for each three  month  period.
On February 19, 2003 the outstanding shares amounting to 1,000,000 were split at
a  forward  stock  split at a ratio of 5 to 1, as a result  4,000,000  shares of
common stock were issued.

LIQUIDITY AND CAPITAL RESOURCES

         Due to its  continuing  losses and  limited  revenues,  the  Company is
dependant on funding of working from its significant  Stockholder in the form of
Stockholder loans.

         Subsequent to the March 24, 2003 change of control as described  above,
the Company  changed its business  focus from  thoroughbred  horse racing to the
pharmaceutical  industry. Until it properly capitalizes itself, it is the intent
of the new  significant  Stockholders  to  provide  sufficient  working  capital
necessary during the transition/integration  period to preserve the integrity of
the  corporate  entity  until the  Company is able to obtain a more  traditional
source  of  financing.  However  there  is  no  binding  obligation  for  either
management or significant Stockholders to provide additional future funding.

         Management  believes  that with its recent  acquisition  of Inyx Pharma
Limited ("Inyx Pharma"),  the Company will have sufficient  working capital from
operations  of its  newly  acquired  subsidiary  to fund its  immediate  capital
requirements.  However there is no formal agreement  between the Company and its
major stockholders to provide any funding at this time.

Item 3. Controls and Procedures.

         Within the 90 days prior to the filing date of this report, the Company
carried out an  evaluation of the  effectiveness  of the design and operation of
its  disclosure  controls and  procedures  pursuant to Exchange Act Rule 13a-14.
This evaluation was done under the supervision and with the participation of the
Company's  Chairman,  and  its  Vice  President  of  Finance.  Based  upon  that


                                       10
<PAGE>

evaluation, they concluded that the Company's disclosure controls and procedures
are  effective in  gathering,  analyzing and  disclosing  information  needed to
satisfy the  Company's  disclosure  obligations  under the Exchange Act. The two
Executive  officers  responsible for the financial  reporting and disclosure are
also in control of the books and records of the Company and are  involved  first
hand in the decision making process of material transactions.

                          PART II -- OTHER INFORMATION



Item 5. Other Information.

SUBSEQUENT EVENTS

         On April 17, 2003 the Company  entered into a Finders'  Fee  Agreements
with five companies (the "Finders") in connection with the proposed  acquisition
by the  Company  of all of the  issued  and  outstanding  shares of Inyx  Pharma
Limited ("Inyx Pharma").  On closing of the proposed acquisition (see below) the
Company issued  2,450,000  restricted  shares of Common Stock to the Finders for
their role in facilitating the transaction

         On April 21, 2003 the Company entered into a two year Business Advisory
and Financial  Consulting Services Agreement ("the Agreement") with a consultant
to provide advice and council regarding the Company's  strategic  business plans
and other  consulting  needs.  As  consideration  for this Agreement the Company
issued 1,500,000 restricted shares of common stock.

         On April 25, 2003 the Company  acquired all the  outstanding  shares of
Inyx Pharma through a share exchange  transaction  whereby the Inyx Stockholders
became the owners of a majority interest in the Company and Inyx Pharma survived
as a subsidiary of the Company.

         On May 1, 2003 the Company  adopted a Stock Option Plan which  provides
for the granting of options for the benefit of employees officers and directors.
The total  number  of  shares  that may be  issued  under  the plan  amounts  to
5,000,000.

         On May 6, 2003 the Company changed its name to Inyx, Inc.

         On May 14, 2003,  the Company's  trading  symbol on the Nasdaq over the
counter bulletin board was changed to "IYXI".

Item 6.  Exhibits and Reports on Form 8-K.

         (a)      Exhibits

                  99.1     -        Certification  of Jack Kachkar under Section
                                    906 of the  Sarbanes-  Oxley  Act of 2002 is
                                    furnished hereby.

                  99.2     -        Certification   of  Rima  Goldshmidt   under
                                    Section  906  of the  Sarbanes-Oxley  Act of
                                    2002 is provided hereby.




                                       11
<PAGE>

         (b)      Reports on Form 8-K.

         Form 8-K filed on February 19, 2003 reporting under Item 5 that a press
release was issued on February 19, 2003, announcing a five for one forward split
of the Company's common stock.

         Form 8-K filed on April 2, 2003  reporting  a change of  control of the
Registrant  under Item 1 and the Change in  Registrant's  Certifying  Accountant
under Item 4.

         Form 8-K  filed on April  28,  2003  reporting  the  conclusion  of the
previously announced  acquisition of all outstanding common stock of Inyx Pharma
Limited by the Company.


































                                       12
<PAGE>

                                   SIGNATURES

In accordance with the  requirements of the Exchange Act, the registrant  caused
this  report to be  signed on its  behalf  by the  undersigned,  thereunto  duly
authorized.

Date:    May 19, 2003



                                                     INYX, INC.


                                                     By:  /s/ Rima Goldshmidt
                                                        ------------------------
                                                        Rima Goldshmidt,
                                                        Vice President Finance


































                                       13
<PAGE>

                                 CERTIFICATIONS
                                 --------------

I, Jack Kachkar, Chairman and acting Chief Executive Officer, certify that:

1. I have reviewed this quarterly  report on Form 10-QSB of Inyx, Inc.  formerly
known as Doblique, Inc. ;

2. Based on my  knowledge,  this  quarterly  report  does not contain any untrue
statement of a material fact or omit to state a material fact  necessary to make
the statements made, in light of the  circumstances  under which such statements
were made, not  misleading  with respect to the period covered by this quarterly
report;

3.  Based  on my  knowledge,  the  financial  statements,  and  other  financial
information  included in this quarterly  report,  fairly present in all material
respects the financial  condition,  results of operations  and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4.  The  registrant's  other  certifying  officers  and  I are  responsible  for
establishing and maintaining  disclosure  controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

         (a)      designed  such  disclosure  controls and  procedures to ensure
                  that  material   information   relating  to  the   registrant,
                  including its consolidated  subsidiaries,  is made known to us
                  by others  within  those  entities,  particularly  during  the
                  period in which this quarterly report is being prepared;

         (b)      evaluated the  effectiveness  of the  registrant's  disclosure
                  controls and  procedures  as of a date within 90 days prior to
                  the filing  date of this  quarterly  report  (the  "Evaluation
                  Date"); and

         (c)      presented in this quarterly  report our conclusions  about the
                  effectiveness of the disclosure  controls and procedures based
                  on our evaluation as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation,  to the registrant's auditors and the audit committee of
registrant's   board  of  directors  (or  persons   performing   the  equivalent
functions):

         (a)      all  significant  deficiencies  in the design or  operation of
                  internal   controls   which   could   adversely   affect   the
                  registrant's ability to record, process,  summarize and report
                  financial  data  and  have  identified  for  the  registrant's
                  auditors any material weaknesses in internal controls; and

         (b)      any fraud,  whether or not material,  that involves management
                  or  other  employees  who  have  a  significant  role  in  the
                  registrant's internal controls; and

6. The  registrant's  other  certifying  officers  and I have  indicated in this
quarterly  report  whether or not there  were  significant  changes in  internal
controls or in other factors that could  significantly  affect internal controls
subsequent to the date of our most recent  evaluation,  including any corrective
actions with regard to significant deficiencies and material weaknesses.



Date:  May 19, 2003



                                                     /s/ Jack Kachkar
                                                     ----------------
                                                     Jack Kachkar


                                       14
<PAGE>



I, Rima Goldshmidt, Vice President of Finance and acting Chief Financial
Officer, certify that:

1. I have reviewed this quarterly  report on Form 10-QSB of Inyx, Inc.  formerly
known as Doblique, Inc. ;

2. Based on my  knowledge,  this  quarterly  report  does not contain any untrue
statement of a material fact or omit to state a material fact  necessary to make
the statements made, in light of the  circumstances  under which such statements
were made, not  misleading  with respect to the period covered by this quarterly
report;

3.  Based  on my  knowledge,  the  financial  statements,  and  other  financial
information  included in this quarterly  report,  fairly present in all material
respects the financial  condition,  results of operations  and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4.  The  registrant's  other  certifying  officers  and  I are  responsible  for
establishing and maintaining  disclosure  controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

         (a)      designed  such  disclosure  controls and  procedures to ensure
                  that  material   information   relating  to  the   registrant,
                  including its consolidated  subsidiaries,  is made known to us
                  by others  within  those  entities,  particularly  during  the
                  period in which this quarterly report is being prepared;

         (b)      evaluated the  effectiveness  of the  registrant's  disclosure
                  controls and  procedures  as of a date within 90 days prior to
                  the filing  date of this  quarterly  report  (the  "Evaluation
                  Date"); and

         (c)      presented in this quarterly  report our conclusions  about the
                  effectiveness of the disclosure  controls and procedures based
                  on our evaluation as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation,  to the registrant's auditors and the audit committee of
registrant's   board  of  directors  (or  persons   performing   the  equivalent
functions):

         (a)      all  significant  deficiencies  in the design or  operation of
                  internal   controls   which   could   adversely   affect   the
                  registrant's ability to record, process,  summarize and report
                  financial  data  and  have  identified  for  the  registrant's
                  auditors any material weaknesses in internal controls; and

         (b)      any fraud,  whether or not material,  that involves management
                  or  other  employees  who  have  a  significant  role  in  the
                  registrant's internal controls; and

6. The  registrant's  other  certifying  officers  and I have  indicated in this
quarterly  report  whether or not there  were  significant  changes in  internal
controls or in other factors that could  significantly  affect internal controls
subsequent to the date of our most recent  evaluation,  including any corrective
actions with regard to significant deficiencies and material weaknesses.



Date:  May 19, 2003



                                                     /s/ Rima Goldshmidt
                                                     -------------------
                                                     Rima Goldshmidt



                                       15